Form 8-K · Current report
News Corp 8-K, filed Sep 8, 2026
- Filed
- CIK
- 0001564708
- Accession no.
- 0001564708-26-000196
Summary
News Corp reported in a Form 8-K that under its 2025 Repurchase Program, authorized July 15, 2025 for up to $1 billion of its Nasdaq-listed Class A and Class B common stock, it bought back 54,641 shares for about $1.67 million on September 4, 2026, bringing total consideration paid under the program to roughly $463.3 million.
Key points
- News Corp is authorized to repurchase up to an aggregate $1 billion of its Class A and Class B common stock under the 2025 Repurchase Program.
- Cumulative buy-backs under the program stood at 11,614,809 shares for about $301.3 million as of the prior day, with approximately $463.3 million in total consideration paid to date.
- The previous day's purchases were made at prices between $30.455 and $30.85; program-to-date prices ranged from $22.20 to $31.58.
- News Corp reported 359,946,996 Class A common shares on issue and named Goldman Sachs & Co. LLC as broker; no ASX-listed CDIs will be repurchased.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 8.01 Other Events. As previously reported, under News Corporation's (the "Company's") stock repurchase program (the "Repurchase Program"), the Company is authorized to acquire from time to time up to $1 billion in the aggregate of the Company's outstanding shares of Class A common stock and Class B common stock. Under the rules of the Australian Securities Exchange (the "ASX"), the Company is required to provide to the ASX, on a daily basis, disclosure of transactions pursuant to the Repurchase Program, if any. The Company also discloses information concerning the Repurchase Program in the Company's quarterly and annual reports. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.